A Phase II Trial of Antiandrogen Withdrawal In Patients with Progressive Prostate Cancer

Pts must have histologically conf. adenocarcinoma of the prostate. Pts must fit into one of the following three classes: 1) be prev. rand. to the flutamide arm of SWOG-8894 as initial HT and compliant with taking medications OR 2) have received an antiandrogen as part of their initial HT for metastatic (Stage D2) prostate ca and should have been on continuous antiandrogen tx OR 3) have received an antiandrogen as part of their initial HT but have not had a diagnosis of metastatic (Stage D2) prostate ca and have been on continuous antiandrogen tx. Pts must be taking an antiandrogen on a regular basis at regis., must have progressive dz at study entry (SWOG-8894 pts must progress by SWOG-8894 criteria), PSA>4 ng/ml, no other therapy w/in 30 days prior to regis. except that specified in SWOG-8894 OR medical castration (Lupron, Zoladex, etc) or surgical castration and antiandrogen, no concomitant chemo, hormone, or biologic response modifier therapy, except LHRH analogues.